Alexion, AstraZeneca Rare Disease will be responsible for all commercial activity for Beyonttra in Japan. “There is significant need for new treatment options for ATTR-CM, a progressive ...

with royalties in the low double digits on net sales of Beyonttra in Japan “There is significant need for new treatment options for ATTR-CM, a progressive, fatal disease, worldwide. This latest ...

JAMA Cardiol. 2024 Dec 4:e244102. Beyonttra is an orally administered near-complete (≥90%) stabilizer of transthyretin (TTR) indicated for the treatment of wild-type or variant transthyretin ...

In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated In the Japanese Phase 3 study, 0% mortality was reported over the 30 ...

with royalties in the low double digits on net sales of Beyonttra in Japan "There is significant need for new treatment options for ATTR-CM, a progressive, fatal disease, worldwide. This latest ...

BEYONTTRA was generally well-tolerated. The most common side effects were mild and included diarrhea and abdominal pain that were resolved without drug discontinuation. For full prescribing ...